FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.
What happened
FDA reviewed the website https://www.mystarthealth.com in August 2025. The site offers compounded semaglutide (semaglutide made by a compounding pharmacy, not an FDA-approved manufacturer) and uses claims including 'Generic Ozempic' and 'Save with generics that offer the same active ingredients and results.' FDA says these claims are false or misleading because compounded drugs are not FDA-approved and the claims imply the products are the same as an FDA-approved product.
What FDA found
The website called its compounded semaglutide 'Generic Ozempic,' falsely implying it is the same as FDA-approved Ozempic.
FDCA section 502(a) [21 U.S.C. § 352(a)]The website said its generics offer 'the same active ingredients and results,' a misleading claim because compounded drugs are not FDA-approved.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]The company introduced or delivered misbranded drugs into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving or delivering misbranded drugs in interstate commerce is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells MyStart Health to take immediate action, including stopping the misleading language, and to send a written response within 15 working days describing steps taken, how it will prevent recurrence, and related documents. If it cannot fully address the matter in that time, it must explain the delay and when it will.
Who should pay attention
- telehealth companies selling compounded semaglutide
- compounding pharmacies and online pharmacies that compare their drugs to brand-name products
- marketing and compliance teams for prescription drug websites
This is a summary. Read the original letter on fda.gov.